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A 45-year-old premenopausal woman was referred to our clinic due to recurring symptoms of uterine ﬁbroids, nine years after a
uterine artery embolization (UAE). At the time of screening, the patient presented with bilateral impairment and narrowing of the
uterine arteries, which increased the risk of arterial perforation during repeated UAE procedures. The patient was subsequently
referred for magnetic resonance imaging-guided focused ultrasound surgery (MRgFUS) treatment. Following the treatment, the
patient experienced a signiﬁcant improvement in symptoms (symptom severity score was reduced from 47 to 12 by 1 year post-
treatment). MR images at 3 months showed a 49% decrease in ﬁbroid volume. There were no adverse events during the treatment
or the follow-up period. This case suggests that MRgFUS can be an eﬀective treatment option for patients with recurrent ﬁbroids
following previous UAE treatment.
1.Introduction
Uterine leiomyoma (ﬁbroid) is the most common repro-
ductive tract tumor in women of reproductive age. Fibroids
have been clinically identiﬁed in at least 25% of women
[1], and pathological analysis suggests that the prevalence of
ﬁbroids may be as high as 77% [2]. Symptomatic ﬁbroids
can signiﬁcantly aﬀect quality of life (QOL) and can result
in heavy and prolonged menstrual ﬂow, urinary frequency,
pelvic pain, abdominal pressure, infertility, and dyspareunia
[3–5].
Surgical treatments for uterine ﬁbroids include hys-
terectomy and myomectomy [6]. Minimally invasive or
noninvasive treatments include uterine artery embolization
(UAE), magnetic resonance imaging-guided focused ultra-
sound surgery (MRgFUS), and hormonal therapy [6–9].
Each of these treatment options, which require minimal or
no hospitalization, enables women to preserve their uteri
[10] and usually minimize complications, recovery time, and
treatment costs [11, 12].
UAE is a minimally invasive, image-guided therapy, in
which the blood supply to the uterine ﬁbroid is blocked
by catheterization, and the ischemic necrosis of the ﬁbroids
is induced by the insertion of embolic particles [13]. The
embolic particles are usually composed of polyvinyl alcohol,
tris-acryl, or gelatin sponge material.
MRgFUS is a noninvasive treatment in which ultrasound
energy, focused on the ﬁbroid in multiple focal spots,
raises the temperature of tissue within the focal zone and
causes coagulative necrosis. MRI guides and monitors the
procedure, thereby providing closed loop anatomical and
thermal feedback [9].
Several measures are used to assess the eﬃcacy of these
minimally invasive or noninvasive treatments, including a
Uterine Fibroids Symptoms Quality Of Life (UFS-QOL)
assessmentquestionnaire[14],ﬁbroidshrinkage,andpatient2 Obstetrics and Gynecology International
(a) (b)
Figure 1: Screening MR images: (a) coronal T2-weighted image showing two ﬁbroids, (b) coronal T1-weighted contrast-enhanced image—
the right ﬁbroid is already nonenhancing, whereas the left one is still viable.
satisfaction. As with any ﬁbroid treatment, besides hys-
terectomy, symptoms can recur following the less invasive
approaches. Consequently, referral to an alternative treat-
ment, after a particular modality has been pursued, is also
a measure of the treatment eﬃcacy.
Diﬀerent patient selection criteria are established for
UAE and MRgFUS treatments. For UAE, submucosal and
pedunculated ﬁbroids may be considered as relative con-
traindications, as is a previous internal iliac or uterine artery
occlusion, or a recent GnRH analogue administration. In
addition, there is insuﬃcient data to advocate UAE as a
means of preserving fertility [15, 16]. For MRgFUS, hyper-
intense ﬁbroids and multiple ﬁbroids may be considered
relative contraindications, as they are diﬃcult to treat. In
addition, in cases where the ultrasound beam is interrupted
by anatomical structures, such as bowels, bones, or nerves,
MRgFUS treatment may be impossible without successful
mitigation techniques [17].
This is the ﬁrst case report of MRgFUS treatment in a
patient with recurring ﬁbroid symptoms following UAE.
2.CaseReport
A 45-year-old premenopausal woman, with a BMI of 22.1
and 2 previous pregnancies, complained of menorrhagia in
1998. Clinical examination showed two intramural ﬁbroids
with volumes of approximately 115 cc and 15 cc. In
November 1998, the patient underwent a UAE, and both
her ﬁbroids were treated. Approximately nine years later,
in 2008, the patient reported the recurrence of symptoms,
including severe menorrhagia and irregular menstrual peri-
ods (symptom severity score of 47). A pelvic MRI including
MR angiography was performed in order to determine
her ﬁbroid status and suitability for an additional UAE.
Two intramural ﬁbroids were observed (Figure 1). The
ﬁrst was an 81 cc ﬁbroid on the right side of the uterus,
whichwasnonenhancingoncontrast-enhancedT1-weighted
images(probablyduetonecrosisfollowingthepreviousUAE
procedure). The second ﬁbroid, which was located on the
left side of the uterus, was 90 cc and was enhancing on
T1-weighted images. An MR angiography revealed that the
right ﬁbroid lacked a blood supply, with an almost invisible
a
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Figure 2: MR angiography. The reason for UAE unsuitability: (a)
narrow left uterine artery, (b) no obvious right uterine artery.
right uterine artery. The left ﬁbroid was supplied only by
the narrow left uterine artery (Figure 2). The left ﬁbroid
was likely a recurring or new ﬁbroid that had not been
treated by the previous UAE. It was recommended that the
patient not undergo an additional UAE, due to the diﬃculty
in approaching the ﬁbroid bilaterally and the increased risk
of arterial perforation during repeated UAE procedures.
Since the patient insisted on a noninvasive treatment for
her symptoms, she was referred to our unit for MRgFUS
treatment.
Following a negative endometrial biopsy result, the left
ﬁbroid was deemed suitable for MRgFUS treatment.
The MRgFUS procedure was performed using the
Exablate 2000 system (InSightec Ltd., Haifa, Israel) and
the 1.5T HDx MRI (GE Healthcare, Milwaukee, U.S.).
Patient preparation included shaving and cleaning of the
abdomen,insertionofaurinarycatheter,andadministration
of conscious sedation (Fentanyl, one ampoule). The patient
was then placed on the ExAblate treatment table with
her abdomen positioned over the ultrasound transducer
bath.Obstetrics and Gynecology International 3
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Figure 3: Treatment images: (a) Sagittal T2-weighted planning image, (b) Sagittal contrast-enhanced T1-weighted posttreatment image
showing 90% of nonenhancing volume on the left ﬁbroid.
1/C1585
Figure 4: Coronal T2-weighted image three months post-treat-
ment, showing 49% volume shrinkage of the treated ﬁbroid.
Pretreatment T2-weighted MR images were obtained
for procedure planning and for targeting the left ﬁbroid.
For the duration of the treatment, 35 sonications were
delivered over approximately 1 hour, and thermal responses
consistent with eﬀective ablation were observed on the real-
time temperature maps. T1-weighted contrast-enhanced
images that were obtained immediately following the pro-
cedure showed a nonperfused volume (NPV) of 81 cc,
which constitutes approximately 90% of the ﬁbroid volume
(Figure 3).
The patient was discharged approximately 30 minutes
after completion of the procedure and reported a return to
normal activity and a regular work schedule after one day.
The patient did not report any pain and was very satisﬁed
with her rapid recovery compared to her previous UAE.
There were no adverse events during or after the treatment.
Three months after the treatment, the patient reported
signiﬁcant symptom improvement. Contrast-enhanced T1-
weightedandT2-weightedMRimages,obtainedatthattime,
revealed shrinkage of the treated ﬁbroid by 49% (Figure 4).
The patient’s SSS was 22, reﬂecting a 25-point decrease from
the base-line score before the MRgFUS treatment. At the
one-year follow-up assessment, her symptom severity score
was further decreased to 12.
3. Discussion
We are currently noticing an increase in the number
of uterine ﬁbroid patients who seek minimally invasive
or non-invasive treatment options. These options include
laparoscopic surgeries, UAE, MRgFUS, and other modalities.
Patients should be made aware of all the treatment
options available for uterine ﬁbroids, including invasive,
minimally invasive or noninvasive procedures. The most
clinically suitable treatment option should be recommended
for each individual patient, according to her medical condi-
tion and personal needs.
UAE treatment may pose an increased risk in cases where
the uterine artery is absent in the area of the ﬁbroid, or
when a highly tortuous uterine artery or ectopic arterial
branches feed the ﬁbroid [18]. Therefore, patients who
present with one of these anatomical features, who have
recurring symptoms and are seeking a minimally invasive
or noninvasive treatment, may be referred for MRgFUS or
hormonal therapy.
This paper demonstrates how patients can potentially
beneﬁt from alternative minimally invasive or noninvasive
treatment options for symptomatic uterine ﬁbroids. Speciﬁ-
cally, MRgFUS treatment can be a good option for patients
who were previously treated with UAE. Additional studies of
the safety and eﬃcacy of MRgFUS following UAE should be
conducted.
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